1
|
Abolarin PO, Amin A, Nafiu AB, Ogundele OM, Owoyele BV. Optimization of Parkinson's disease therapy with plant extracts and nutrition's evolving roles. IBRO Neurosci Rep 2024; 17:1-12. [PMID: 38872839 PMCID: PMC11167367 DOI: 10.1016/j.ibneur.2024.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 05/01/2024] [Accepted: 05/24/2024] [Indexed: 06/15/2024] Open
Abstract
Parkinson's disease (PD) is a neurodegenerative disease characterized by death of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Death of dopaminergic cells in the SNpc leads to manifestations of motor dysfunction and non-motor symptoms of PD. The progression of PD symptoms severely affects the quality of life of patients and poses socio-economic problems to families and society at large. The clinical and neuropathological characteristics of PD are triggered by multiple factors such as oxidative stress, neuroinflammation, mitochondrial dysfunction, and protein aggregation. Notwithstanding the advancements in pharmacological therapy in PD management, there is burgeoning interest in alternative and complementary approaches, essentially nutrition and plant extracts strategies. This review gives widespread analysis of the role of nutrition and plant extracts in the management of PD. Studies that investigated the effects of various dietary compounds and plant extract on PD symptoms and progression were reviewed from existing literatures. Nutraceuticals, including vitamins and phytochemicals such as Mucuna pruriens have shown potential neuroprotective functions in preclinical and clinical studies. Indeed, these strategies ameliorate mitochondrial dysfunction, oxidative stress, and neuroinflammation, all which are implicated in the pathogenesis of PD. The neuroprotective mechanisms of nutrition and plant extracts in PD, with emphasis on their capacity to target multiple pathways implicated in PD are discussed. Additionally, challenges and limitations related with translating preclinical findings into clinical practice including standardization of dosing regimens, bioavailability, and inter-individual variability are discussed. Largely, this review elucidates on the role of nutrition and plant extracts as adjunctive therapy in PD management.
Collapse
Affiliation(s)
- Patrick Oluwole Abolarin
- Department of Physiology, Faculty of Basic Medical Sciences, University of Ilorin, Ilorin, Kwara State, Nigeria
| | - Abdulbasit Amin
- Department of Physiology, Faculty of Basic Medical Sciences, University of Ilorin, Ilorin, Kwara State, Nigeria
| | | | - Olalekan Michael Ogundele
- Department of Comparative Biomedical Sciences, Louisiana State University, School of Veterinary Medicine, Baton Rouge, LA, USA
| | - Bamidele Victor Owoyele
- Department of Physiology, Faculty of Basic Medical Sciences, University of Ilorin, Ilorin, Kwara State, Nigeria
| |
Collapse
|
2
|
Sakata M, Miyamoto K, Koh J, Nagashima Y, Kondo T, Ito H. Japanese Mucuna pruriens (Hasshou Beans) Showed Fast-acting and Long-lasting Effects in Parkinson's Disease. Intern Med 2024; 63:2773-2779. [PMID: 38462520 DOI: 10.2169/internalmedicine.3171-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/12/2024] Open
Abstract
Objective Mucuna pruriens (MP) is a legume whose seeds contain levodopa (LD), which has potential therapeutic effects against Parkinson's disease (PD). However, further research is needed to thoroughly evaluate its efficacy and safety for treating this condition. In this study, we analyzed the pharmacokinetics of MP grown in Japan and investigated its mechanism of action in PD. Methods MP seeds ground after roasting (containing 4.02% LD per MP powder) were used as the reagent and compared with an equivalent LD/carbidopa (CD) preparation. This clinical trial was conducted using a crossover design among PD patients attending our institution. Each patient received a single dose of 100/10 mg LD/CD tablets and 11 g of MP reagent. Results Among the seven patients with PD, MP prolonged the ON time 2-fold compared to LD/CD. The LD concentrations after MP intake were higher than those after LD/CD intake, whereas dyskinesia did not increase. An analysis of the LD metabolites showed that the 3-O-methyl-dopa/LD metabolic ratio was significantly lower after MP ingestion than after LD/CD ingestion, indicating that MP has a catechol-O-methyl transferase inhibitory effect. Conclusions This is the first report of a pharmacokinetic analysis conducted on actual patients with PD showing that MP significantly prolongs the ON time. The advantages of MP as a treatment for PD have been confirmed: it is inexpensive, as effective as LD, works faster and longer than LD, and does not increase dyskinesia.
Collapse
Affiliation(s)
- Mayumi Sakata
- Department of Neurology, Wakayama Medical University, Japan
| | | | - Jinsoo Koh
- Department of Neurology, Wakayama Medical University, Japan
| | | | | | - Hidefumi Ito
- Department of Neurology, Wakayama Medical University, Japan
| |
Collapse
|
3
|
Mthana MS, Mthiyane DMN. High dietary Mucuna pruriens utilis seed meal compromises growth performance, carcass traits, haemato-biochemistry, and meat quality of broilers. Trop Anim Health Prod 2024; 56:310. [PMID: 39352513 PMCID: PMC11445329 DOI: 10.1007/s11250-024-04120-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2024] [Accepted: 09/11/2024] [Indexed: 10/04/2024]
Abstract
Usage of soyabean meal (SBM) in broiler diets is economically and environmentally unsustainable thus necessitating investigation of alternative protein sources. Therefore, this study investigated effects of incremental inclusion levels of Mucuna pruriens utilis seed meal (MSM) for partial substitution of SBM in broiler diets. In a completely randomized design (CRD), 400 day-old Ross 308 chicks were allotted to 5 iso-caloric-nitrogenous MSM-containing (0, 5, 10, 15, and 20%) dietary treatments. Each treatment was replicated 8 times, with each pen having 10 birds, during starter (d1 - 14), grower (d15 - 28), and finisher (d29 - 42) phases. Results showed that dietary MSM decreased feed intake (FI: quadratic: P < 0.001), body weight gain (BWG: linear: P < 0.001), and feed conversion efficiency (FCE: linear: P < 0.001) as it linearly decreased slaughter weight (SW: P < 0.001), hot carcass weight (HCW: P < 0.001), cold carcass weight (CCW: P < 0.001), dressing percentage (P < 0.001), and breast weight (P < 0.05). In contrast, dietary MSM linearly increased the weights of the liver (P < 0.01), proventriculus (P < 0.001), gizzard (P < 0.001), duodenum (P = 0.01), jejunum (P < 0.001), ileum (P < 0.001), caecum (P < 0.01), and colon (P < 0.01). Also, dietary MSM quadratically increased blood heterophils (P < 0.05) and alkaline phosphatase activity (P < 0.05) of the chickens whilst linearly increasing their serum amylase (P = 0.001) and lipase (P = 0.001) activities and linearly decreasing their serum symmetric dimethylarginine (SDMA: P = 0.001) and cholesterol (P < 0.05). Further, dietary MSM linearly decreased chicken breast meat ultimate pH (P < 0.05) whilst linearly increasing its cooking loss (P < 0.01), drip loss (P < 0.05) and shear force (P < 0.01). In conclusion, dietary MSM compromised growth performance, carcass characteristics, and meat quality of broilers as it increased the weights of their digestive-metabolic organs.
Collapse
Affiliation(s)
- Makiwa Simeon Mthana
- Department of Animal Science, School of Agricultural Sciences, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Private Bag X 2046, Mmabatho, 2735, South Africa
| | - Doctor Mziwenkosi Nhlanhla Mthiyane
- Department of Animal Science, School of Agricultural Sciences, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Private Bag X 2046, Mmabatho, 2735, South Africa.
- Food Security and Safety Focus Area, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Mmabatho, 2735, South Africa.
| |
Collapse
|
4
|
Mthana MS, Mthiyane DMN. Low dietary oyster mushroom spent substrate limitedly ameliorates detrimental effects of feeding combined marula seed cake and mucuna seed meal as soya bean replacements in broiler chickens. Trop Anim Health Prod 2024; 56:37. [PMID: 38194011 PMCID: PMC10776489 DOI: 10.1007/s11250-023-03878-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 12/15/2023] [Indexed: 01/10/2024]
Abstract
This study investigated ameliorative effects of dietary oyster mushroom (Pleurotus ostreatus) spent substrate (OMSS) in broiler chickens fed diets supplemented with combined marula seed cake (MSC) and mucuna seed meal (MSM) replacing soya bean meal (SBM). In a completely randomised design (CRD), 400 day-old Ross 308 chicks were randomly allocated to 5 iso-nitrogenous-energetic diets (control with 100% SBM, control with 60% MSC and 40% MSM replacing SBM (MSC + MSM), MSC + MSM with 1.25% OMSS, MSC + MSM with 2.5% OMSS, and MSC + MSM with 5% OMSS) each with 8 replicate pens of 10 during starter, grower and finisher phases. Dietary MSC + MSM decreased (P < 0.001) feed intake (FI), body weight gain (BWG), and feed conversion efficiency (FCE); slaughter weight, hot carcass weight (HCW), cold carcass weight (CCW), breast weight, and back lengths (P < 0.001); serum SDMA and alanine transaminase (P < 0.05). In contrast, it increased the weights of the thigh (P < 0.001), wing (P < 0.01), liver (P < 0.001), proventriculus (P < 0.001), gizzard (P < 0.001), duodenum (P < 0.001), jejunum (P < 0.001), ileum (P < 0.001), and caecum (P < 0.01) and serum alkaline phosphatase (P < 0.05) and cholesterol (P < 0.01). Further, it increased meat redness and decreased its hue angle at 45 min post-slaughter (P < 0.01) whilst it decreased its pH (P < 0.01) and increased its shear force (P < 0.05) at 24 h post-slaughter. Compared to higher levels, low (1.25%) dietary OMSS improved, though limitedly, FI, BWG, and FCE at grower and finisher phases only (P < 0.001) whilst it reversed MSC plus MSM-induced deleterious effects on slaughter weight, HCW, and CCW (P < 0.001) and increases in gizzard weight (P < 0.001) and meat shear force at 24 h post-slaughter (P < 0.05). Otherwise, OMSS generally decreased (P < 0.05) serum SDMA and alanine transaminase whilst it abrogated and augmented increases in serum alkaline phosphatase (P < 0.05) and cholesterol (P < 0.01), respectively, and reversed the increase and decrease in meat redness (P < 0.01) and hue angle (P < 0.05), respectively. In conclusion, dietary replacement of SBM with combined MSC plus MSM induced deleterious effects in broiler chickens that were limitedly abrogated by low (1.25%) inclusion level of OMSS.
Collapse
Affiliation(s)
- Makiwa Simeon Mthana
- Department of Animal Science, School of Agricultural Sciences, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Private Bag X 2046, Mmabatho, 2735, South Africa
| | - Doctor Mziwenkosi Nhlanhla Mthiyane
- Department of Animal Science, School of Agricultural Sciences, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Private Bag X 2046, Mmabatho, 2735, South Africa.
- Food Security and Safety Focus Area, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Mmabatho, 2735, South Africa.
| |
Collapse
|
5
|
Zungu PN, Mthiyane DMN, Mazibuko-Mbeje SE, Ogwuegbu MC. Dietary supplementation of low levels of unprocessed Mucuna pruriens utilis seed meal induces mild antinutritional entero-physio-metabolic perturbations without compromising performance and meat quality in finisher broilers. Trop Anim Health Prod 2023; 55:336. [PMID: 37770670 PMCID: PMC10539458 DOI: 10.1007/s11250-023-03760-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 09/12/2023] [Indexed: 09/30/2023]
Abstract
The rapidly growing world human population accentuates the need for improved production especially of protein-rich food. Broiler meat production offers opportunity to ensure security of this food. However, the production of modern broilers is not only limited by high feed costs due to dietary use of expensive energy and protein sources but also their meat possesses undesirable quality attributes. This study thus examined the effect of dietary Mucuna pruriens utilis seed meal (MSM) on growth performance, blood profile, carcass traits, and meat quality in finisher broiler chickens. In a completely randomised design (CRD), 320 21-day-old chicks were randomly allocated to 32 pens in which they were allotted 4 dietary treatments with 0, 2.5, 5, and 10% MSM, each with 8 replicate pens of 10 birds, for 28 days. Growth performance, carcass characteristics, internal organs, haemato-biochemistry, and meat quality were measured. Results showed that dietary MSM did not affect (P > 0.05) broiler performance, weights, and lengths of carcass cuts and internal organs, haematology, and meat quality. The only exception was MSM-induced increase in duodenal weight (linear, P < 0.05) and serum phosphorus (quadratic, P = 0.05) in contrast to a decrease in procalcitonin (quadratic, P < 0.01) and serum levels of total protein (linear, P < 0.05; and quadratic, P < 0.01), albumin (quadratic, P < 0.05), and bilirubin (quadratic, P = 0.001). Therefore, MSM could be supplemented up to 10% without compromising performance, carcass traits, internal organs, haemato-biochemistry, and meat quality in finisher broiler diets.
Collapse
Affiliation(s)
- Pretty Ntombizethu Zungu
- Department of Animal Science, School of Agricultural Sciences, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Private Bag X 2046, Mmabatho, 2735 South Africa
| | - Doctor Mziwenkosi Nhlanhla Mthiyane
- Department of Animal Science, School of Agricultural Sciences, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Private Bag X 2046, Mmabatho, 2735 South Africa
- Food Security and Safety Focus Area, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Mmabatho, 2735 South Africa
| | - Sithandiwe Eunice Mazibuko-Mbeje
- Department of Biochemistry, North-West University, Mmabatho, 2745 South Africa
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
| | - Mercy Chisara Ogwuegbu
- Food Security and Safety Focus Area, Faculty of Natural and Agricultural Sciences, North-West University (Mahikeng Campus), Mmabatho, 2735 South Africa
- Department of Animal Science, Faculty of Agriculture, University of Nigeria, Nsukka, Enugu State 410001 Nigeria
| |
Collapse
|
6
|
Chittasupho C, Tadtong S, Vorarat S, Imaram W, Athikomkulchai S, Samee W, Sareedenchai V, Thongnopkoon T, Okonogi S, Kamkaen N. Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson’s Disease. Pharmaceutics 2022; 14:pharmaceutics14051079. [PMID: 35631666 PMCID: PMC9147856 DOI: 10.3390/pharmaceutics14051079] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 05/14/2022] [Accepted: 05/16/2022] [Indexed: 01/27/2023] Open
Abstract
The first line therapy of patients with Parkinson’s disease, a neurodegenerative disorder caused by the degeneration of dopaminergic neurons, is levodopa (L-dopa) given orally. Recently, the presence of natural L-dopa in the seed of Mucuna pruriens, a tropical legume in the Fabaceae family, was reported and it showed superior efficiency compared with synthetic L-dopa. Therefore, this study aimed to examine the phytochemical compounds, particularly for natural L-dopa, in M. pruriens seed extract and subsequently prepare a nanogel containing the extract prior to incorporation into a jelly formulation for use as a functional food in elderly patients with Parkinson’s disease. The results show that M. pruriens seed extract contains phenolic compounds, flavonoids, tannins, alkaloids, terpenoids, and saponins. The quantitative analysis performed by the HPLC method revealed that spray-dried M. pruriens seed extract contained 5.59 ± 0.21% L-dopa. M. pruriens seed extract possesses a ferric-reducing antioxidant power and shows free-radical scavenging activity, determined by DPPH and ABTS methods, suggesting a distinctive antioxidant ability of the extract. M. pruriens seed extract at 10 ng/mL did not show cytotoxicity against a neuronal cell line (SH-SY5Y cells), kidney cells (HEK293 cells), or Caco-2 cells. Nanogel of M. pruriens seed extract prepared by ionic gelation had the hydrodynamic diameter, polydispersity index and zeta potential value of 384.53 ± 11.24 nm, 0.38 ± 0.05, and −11.23 ± 1.15 mV, respectively. The transepithelial transport of L-dopa in M. pruriens seed-extract nanogel through Caco-2 cells was measured. Nanogel containing M. pruriens seed extract at the concentration of 10 ng/mL exhibited neuroprotective activity. A jelly formulation containing M. pruriens seed-extract nanogel was successfully developed. The prepared jelly exhibited the acceptable physical and microbiological stabilities upon 6 months of the stability test. The half-life of natural L-dopa in jelly were 3.2, 0.9, and 0.6 years for storage conditions at 4, 30, and 40 °C, respectively, indicating the thermal degradation of natural L-dopa. The prepared jelly containing natural L-dopa from M. pruriens seed extract with the prominent antioxidant activity is a promising option for elderly patients suffering from Parkinson’s disease.
Collapse
Affiliation(s)
- Chuda Chittasupho
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Mueang, Chiang Mai 50200, Thailand; (C.C.); (S.O.)
- Research Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Chiang Mai University, Mueang, Chiang Mai 50200, Thailand
| | - Sarin Tadtong
- Department of Pharmacognosy, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nahonnayok 26120, Thailand; (S.T.); (S.A.); (V.S.)
| | - Suwanna Vorarat
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nahonnayok 26120, Thailand; (S.V.); (W.S.)
| | - Witcha Imaram
- Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Kasetsart University, Chatuchak, Bangkok 10900, Thailand;
| | - Sirivan Athikomkulchai
- Department of Pharmacognosy, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nahonnayok 26120, Thailand; (S.T.); (S.A.); (V.S.)
| | - Weerasak Samee
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nahonnayok 26120, Thailand; (S.V.); (W.S.)
| | - Vipaporn Sareedenchai
- Department of Pharmacognosy, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nahonnayok 26120, Thailand; (S.T.); (S.A.); (V.S.)
| | - Thanu Thongnopkoon
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nakhonnayok 26120, Thailand;
| | - Siriporn Okonogi
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Mueang, Chiang Mai 50200, Thailand; (C.C.); (S.O.)
- Research Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Chiang Mai University, Mueang, Chiang Mai 50200, Thailand
| | - Narisa Kamkaen
- Department of Industrial Pharmacy, School of Pharmacy, Eastern Asia University, Thanyaburi, Pathum Thani 12110, Thailand
- Correspondence: ; Tel.: +66-2577-1028 (ext. 373)
| |
Collapse
|
7
|
Rajagopal M, Paul AK, Lee MT, Joykin AR, Por CS, Mahboob T, Salibay CC, Torres MS, Guiang MMM, Rahmatullah M, Jahan R, Jannat K, Wilairatana P, de Lourdes Pereira M, Lim CL, Nissapatorn V. Phytochemicals and Nano-Phytopharmaceuticals Use in Skin, Urogenital and Locomotor Disorders: Are We There? PLANTS 2022; 11:plants11091265. [PMID: 35567266 PMCID: PMC9099949 DOI: 10.3390/plants11091265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 04/29/2022] [Accepted: 04/30/2022] [Indexed: 12/02/2022]
Abstract
Nanomedicines emerged from nanotechnology and have been introduced to bring advancements in treating multiple diseases. Nano-phytomedicines are synthesized from active phytoconstituents or plant extracts. Advancements in nanotechnology also help in the diagnosis, monitoring, control, and prevention of various diseases. The field of nanomedicine and the improvements of nanoparticles has been of keen interest in multiple industries, including pharmaceutics, diagnostics, electronics, communications, and cosmetics. In herbal medicines, these nanoparticles have several attractive properties that have brought them to the forefront in searching for novel drug delivery systems by enhancing efficacy, bioavailability, and target specificity. The current review investigated various therapeutic applications of different nano-phytopharmaceuticals in locomotor, dermal, reproductive, and urinary tract disorders to enhance bioavailability and efficacy of phytochemicals and herbal extracts in preclinical and in vitro studies. There is a lack of clinical and extensive preclinical studies. The research in this field is expanding but strong evidence on the efficacy of these nano-phytopharmaceuticals for human use is still limited. The long-term efficacy and safety of nano-phytopharmaceuticals must be ensured with priority before these materials emerge as common human therapeutics. Overall, this review provides up-to-date information on related contemporary research on nano-phytopharmaceuticals and nano-extracts in the fields of dermatological, urogenital, and locomotor disorders.
Collapse
Affiliation(s)
- Mogana Rajagopal
- Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur 56000, Malaysia; (M.R.); (M.-T.L.); (A.R.J.); (C.-S.P.)
| | - Alok K. Paul
- School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia;
| | - Ming-Tatt Lee
- Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur 56000, Malaysia; (M.R.); (M.-T.L.); (A.R.J.); (C.-S.P.)
| | - Anabelle Rose Joykin
- Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur 56000, Malaysia; (M.R.); (M.-T.L.); (A.R.J.); (C.-S.P.)
| | - Choo-Shiuan Por
- Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur 56000, Malaysia; (M.R.); (M.-T.L.); (A.R.J.); (C.-S.P.)
| | - Tooba Mahboob
- School of Allied Health Sciences and World Union for Herbal Drug Discovery (WUHeDD), Walailak University, Nakhon Si Thammarat 80160, Thailand;
| | - Cristina C. Salibay
- Biologica Sciences Department, College of Science and Computer Studies, De La Salle University, Dasmarinas 4114, Philippines; (C.C.S.); (M.S.T.)
| | - Mario S. Torres
- Biologica Sciences Department, College of Science and Computer Studies, De La Salle University, Dasmarinas 4114, Philippines; (C.C.S.); (M.S.T.)
| | - Maria Melanie M. Guiang
- Department of Biology, College of Arts and Sciences, Central Mindanao University, Bukidnon 8710, Philippines;
- Center of Biodiversity Research and Extension in Mindanao (CEBREM), Central Mindanao University, Bukidnon 8710, Philippines
| | - Mohammed Rahmatullah
- Department of Biotechnology & Genetic Engineering, University of Development Alternative, Lalmatia, Dhaka 1207, Bangladesh; (M.R.); (R.J.); (K.J.)
| | - Rownak Jahan
- Department of Biotechnology & Genetic Engineering, University of Development Alternative, Lalmatia, Dhaka 1207, Bangladesh; (M.R.); (R.J.); (K.J.)
| | - Khoshnur Jannat
- Department of Biotechnology & Genetic Engineering, University of Development Alternative, Lalmatia, Dhaka 1207, Bangladesh; (M.R.); (R.J.); (K.J.)
| | - Polrat Wilairatana
- Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
- Correspondence: (P.W.); (V.N.)
| | - Maria de Lourdes Pereira
- CICECO—Aveiro Institute of Materials, Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal;
| | - Chooi Ling Lim
- Division of Applied Biomedical Science and Biotechnology, School of Health Sciences, International Medical University, Kuala Lumpur 57000, Malaysia;
| | - Veeranoot Nissapatorn
- School of Allied Health Sciences and World Union for Herbal Drug Discovery (WUHeDD), Walailak University, Nakhon Si Thammarat 80160, Thailand;
- Correspondence: (P.W.); (V.N.)
| |
Collapse
|
8
|
Echeverria V, Echeverria F, Barreto GE, Echeverría J, Mendoza C. Estrogenic Plants: to Prevent Neurodegeneration and Memory Loss and Other Symptoms in Women After Menopause. Front Pharmacol 2021; 12:644103. [PMID: 34093183 PMCID: PMC8172769 DOI: 10.3389/fphar.2021.644103] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2020] [Accepted: 04/15/2021] [Indexed: 12/11/2022] Open
Abstract
In mammals, sexual hormones such as estrogens play an essential role in maintaining brain homeostasis and function. Estrogen deficit in the brain induces many undesirable symptoms such as learning and memory impairment, sleep and mood disorders, hot flushes, and fatigue. These symptoms are frequent in women who reached menopausal age or have had ovariectomy and in men and women subjected to anti-estrogen therapy. Hormone replacement therapy alleviates menopause symptoms; however, it can increase cardiovascular and cancer diseases. In the search for therapeutic alternatives, medicinal plants and specific synthetic and natural molecules with estrogenic effects have attracted widespread attention between the public and the scientific community. Various plants have been used for centuries to alleviate menstrual and menopause symptoms, such as Cranberry, Ginger, Hops, Milk Thistle, Red clover, Salvia officinalis, Soy, Black cohosh, Turnera diffusa, Ushuva, and Vitex. This review aims to highlight current evidence about estrogenic medicinal plants and their pharmacological effects on cognitive deficits induced by estrogen deficiency during menopause and aging.
Collapse
Affiliation(s)
- Valentina Echeverria
- Facultad de Ciencias de la Salud, Universidad San Sebastian, Concepcion, Chile
- Research and Development Service, Bay Pines VA Healthcare System, Bay Pines, FL, Unites States
| | | | - George E. Barreto
- Department of Biological Sciences, University of Limerick, Limerick, Ireland
- Health Research Institute, University of Limerick, Limerick, Ireland
| | - Javier Echeverría
- Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile
| | - Cristhian Mendoza
- Facultad de Ciencias de la Salud, Universidad San Sebastian, Concepcion, Chile
| |
Collapse
|
9
|
Compounds from Mucuna pruriens Seeds and their Neuroprotective Effects. Chem Nat Compd 2021. [DOI: 10.1007/s10600-021-03425-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Rai SN, Chaturvedi VK, Singh P, Singh BK, Singh MP. Mucuna pruriens in Parkinson's and in some other diseases: recent advancement and future prospective. 3 Biotech 2020; 10:522. [PMID: 33194526 DOI: 10.1007/s13205-020-02532-7] [Citation(s) in RCA: 65] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 10/28/2020] [Indexed: 12/12/2022] Open
Abstract
Mucuna pruriens (Mp) is an annual and perennial legume which belongs to the family Fabaceae having different types of therapeutic activity. Anti-oxidative, anti-inflammatory, anti-epileptic, anti-microbial, etc. are the example of some most common activities of Mp. It is widely utilized as a potent aphrodisiac. The anti-Parkinsonian activity of Mp was explored since the nineteenth century. The neuroprotective activity of Mp was shown by several researchers. Levodopa (L-DOPA) is the important constituents responsible for the anti-Parkinsonian activity of Mp. Apart from L-DOPA, several other important bioactive components like Ursolic acid (UA) and Betulinic acid (BA) also exhibit a similar neuroprotective activity. Parkinson's disease (PD) is mainly sporadic. A very small proportion shows the genetic nature of PD. The anti-Parkinsonian activity of Mp was explored in different toxin-induced PD models as like MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), Rotenone, Paraquat, 6-hydroxydopamine (6-OHDA) as suggested by several pieces of literature. Various parts of Mp's like seed, leaf, and stem exhibit potent neuroprotective attributes. Among different parts, seeds are widely utilized as anti-PD agents because of the higher percentage of L-DOPA. Besides anti-PD activity, Mp's neuroprotective potential was also explored in the ischemic model of stroke that also shows positive results. Recently, several clinical trials have been performed on the anti-PD activity of Mp on PD patients that show convincing results. Although, a small population-based study needs to be further validated in the broader population. Apart from anti-PD activity, Mp also shows its therapeutic activity in some other diseases like cancer, diabetes, skin infection, anemia, antihypertensive, etc. that are summarized in Table 1. In this review, we have discussed the anti-PD potential of Mp in the sporadic and genetic model along with some clinical trials that have performed on PD patients. Some other activity of Mp is also summarized in this review. There is a strong need to test the efficacy of Mp in some other neurodegenerative diseases along with PD. Following this, this review emphasizes the role of Mp in PD systematically through literature analysis available to date. [Table: see text].
Collapse
|
11
|
Du W, Liang X, Wang S, Lee P, Zhang Y. The Underlying Mechanism of Paeonia lactiflora Pall. in Parkinson's Disease Based on a Network Pharmacology Approach. Front Pharmacol 2020; 11:581984. [PMID: 33381034 PMCID: PMC7768820 DOI: 10.3389/fphar.2020.581984] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Accepted: 10/09/2020] [Indexed: 12/12/2022] Open
Abstract
Background: Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, yet as of currently, there is no disease-modifying therapy that could delay its progression. Paeonia lactiflora Pall. is the most frequently used herb in formulas for PD in Traditional Chinese Medicine and also a potential neuroprotective agent for neurodegenerative diseases, while its mechanisms remain poorly understood. In this study, we aim to explore the underlying mechanism of P. lactiflora in treating PD utilizing a network pharmacology approach. Methods: The protein targets of P. lactiflora ingredients and PD were first obtained from several databases. To clarify the key targets, a Protein-Protein-Interaction (PPI) network was constructed and analyzed on the String database, and then enrichment analysis was performed by the Metascape platform to determine the main Gene Ontology biological processes and Kyoto Encyclopedia of Genes and Genomes pathways. Finally, the Ingredient-Target-Pathway (I-T-P) network was constructed and analyzed by Cytoscape software. Results: Six active ingredients of P. lactiflora (kaempferol, ß-sitosterol, betulinic acid, palbinone, paeoniflorin and (+)-catechin) as well as six core targets strongly related to PD treatment [AKT1, interleukin-6, CAT, Tumor necrosis factor (TNF), CASP3, and PTGS2] were identified. The main pathways were shown to involve neuroactive ligand-receptor interaction, Calcium signaling pathway, PI3-Akt signaling pathway, TNF signaling pathway, and apoptosis signaling pathway. The main biological process included the regulation of neurotransmitter levels. Conclusion: P. lactiflora may retard neurodegeneration by reducing neuroinflammation, inhibiting intrinsic and extrinsic apoptosis, and may improve motor and non-motor symptoms by regulating the levels of neurotransmitters. Our study has revealed the mechanism of P. lactiflora in the treatment of PD and may contribute to novel drug development for PD.
Collapse
Affiliation(s)
- Wanqing Du
- Graduate School, Beijing University of Chinese Medicine, Beijing, China.,Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Xiao Liang
- Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Shanze Wang
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
| | - Philip Lee
- Graduate School, Beijing University of Chinese Medicine, Beijing, China
| | - Yunling Zhang
- Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.,Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China
| |
Collapse
|
12
|
Knowing Your Beans in Parkinson's Disease: A Critical Assessment of Current Knowledge about Different Beans and Their Compounds in the Treatment of Parkinson's Disease and in Animal Models. PARKINSON'S DISEASE 2019; 2019:1349509. [PMID: 31781363 PMCID: PMC6875167 DOI: 10.1155/2019/1349509] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 09/21/2019] [Accepted: 10/03/2019] [Indexed: 01/07/2023]
Abstract
This review contains a critical appraisal of current knowledge about the use of beans in both animal models and patients with Parkinson's disease (PD). The potential beneficial effects of beans in PD are increasingly being touted, not only in scientific journals but also by the lay media. While there is a long tradition in Ayurvedic medicine of prescribing extracts from Mucuna pruriens (MP), whose seeds contain 5% L-3,4-dihydroxyphenylalanin (L-DOPA), many other beans also contain L-DOPA (broad beans, common beans, and soybeans) or have other ingredients (coffee and cocoa) that may benefit PD patients. Indeed, bean-derived compounds can elicit neuroprotective effects in animal models of PD, while several studies in human PD patients have shown that motor performance can improve after ingestion of bean extracts. However, there are several arguments countering the view that beans serve as a natural therapy for PD: (i) the results from animal PD models are not necessarily directly applicable to humans; (ii) beans have many bioactive ingredients, some of which can be harmful in large doses; (iii) studies in human PD patients are scarce and only report on the effects of single doses or the administration of bean extract over short periods of time; and (iv) no data on long-term efficacy or side effects of bean therapy are available. Therefore, reservations about the use of beans as a "natural" therapy for PD seem to be justified.
Collapse
|
13
|
Singh SK, Dhawan SS, Lal RK, Shanker K, Singh M. Biochemical characterization and spatio-temporal analysis of the putative L-DOPA pathway in Mucuna pruriens. PLANTA 2018; 248:1277-1287. [PMID: 30105476 DOI: 10.1007/s00425-018-2978-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 08/06/2018] [Indexed: 06/08/2023]
Abstract
Transcriptome analysis and biochemical characterization of the putative l-3,4-dihydroxyphenylalanine (l-DOPA) pathway in Mucuna pruriens (L.) DC have been performed. Spatio-temporal quantification of the putative l-DOPA biosynthetic pathway genes and its correlation with respective metabolites was established. l-tyrosine, l-DOPA, and dopamine from all plant parts were quantified. The de novo transcriptome analysis was performed using leaves of the selected M. pruriens mutant T-IV-9 during maturity. The putative L-DOPA pathway and its regulatory genes were retrieved from transcriptome data and the L-DOPA pathway was biochemically characterized. The spatial and temporal gene expression for the L-DOPA pathway was identified with respect to the chemical constituents. L-tyrosine, L-DOPA, and dopamine contents were highest in leaves during maturity (about 170-day-old plants). The polyphenol oxidase (PPO) was highly expressed in tender stems (230-fold higher as compared to seeds) as well as a high L-DOPA content. The PPO gene was highly expressed in leaves (3367.93 in FPKM) with a 79-fold increase compared to control plants during maturity. L-DOPA was found in every part with varied levels. The highest L-DOPA content was found in mature dried seed (3.18-5.8%), whereas the lowest amount was recorded in mature and dried leaves. The reproductive parts of the plant had a higher amount of L-DOPA content (0.9-5.8%) compared to the vegetative parts (0.2-0.91%). Various amino acid transporters and permeases were expressed in M. pruriens. The transcripts of dopa decarboxylase (DDC) were found in almost all parts of the plant, but its higher content was limited to the leaf.
Collapse
Affiliation(s)
- Susheel Kumar Singh
- Biotechnology Division, CSIR-Central Institute of Medicinal and Aromatic Plants P.O.-CIMAP, Lucknow, 226015, India
| | - Sunita Singh Dhawan
- Biotechnology Division, CSIR-Central Institute of Medicinal and Aromatic Plants P.O.-CIMAP, Lucknow, 226015, India.
| | - Raj Kishori Lal
- Genetics and Plant Breeding Division, CSIR-Central Institute of Medicinal and Aromatic Plants P.O.-CIMAP, Lucknow, 226015, India
| | - Karuna Shanker
- Analytical Chemistry Division, CSIR-Central Institute of Medicinal and Aromatic Plants P.O.-CIMAP, Lucknow, 226015, India
| | - Manju Singh
- Analytical Chemistry Division, CSIR-Central Institute of Medicinal and Aromatic Plants P.O.-CIMAP, Lucknow, 226015, India
| |
Collapse
|
14
|
Adi YK, Widayanti R, Pangestiningsih TW. n-Propanol extract of boiled and fermented koro benguk ( Mucuna pruriens seed) shows a neuroprotective effect in paraquat dichloride-induced Parkinson's disease rat model. Vet World 2018; 11:1250-1254. [PMID: 30410229 PMCID: PMC6200579 DOI: 10.14202/vetworld.2018.1250-1254] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Accepted: 07/26/2018] [Indexed: 11/16/2022] Open
Abstract
Aim: n-Propanol extracts from fresh, boiled, and fermented seeds were studied to evaluate their neuroprotective effects in a Parkinson’s disease (PD) rat model, based on the total number of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). Materials and Methods: Rats were induced with paraquat dichloride at a dosage of 7 mg/kg BW intraperitoneally twice a week and at the same time supplemented with extract at a dosage of 70 mg/kg BW orally every day for 3 weeks. On the 24th day, all rats were perfused and fixed with 4% paraformaldehyde. The left part of the SNpc was processed for immunohistochemical staining with tyrosine hydroxylase (TH)-antibody. The total number of DA neurons in SNpc was evaluated with a stereological method. Results: TH-immunoreactive cells found in the SNpc were identified as DA neurons. The average total number of DA neurons in the SNpc increased significantly in the PD rat model that was given an n-propanol extract of boiled and fermented seeds compared with a control PD rat model. Surprisingly, there was no significant difference in the average total number of DA neurons in SNpc between the PD rat model that was given n-propanol extract of fresh seeds and the control PD rat model. Conclusion: n-Propanol extract of boiled and fermented seeds could produce a higher neuroprotective effect against DA neuron than fresh seeds in a PD rat model.
Collapse
Affiliation(s)
- Yosua Kristian Adi
- Master Program of Veterinary Science, Faculty of Veterinary Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | - Rini Widayanti
- Department of Biochemistry, Faculty of Veterinary Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | - Tri Wahyu Pangestiningsih
- Department of Anatomy, Faculty of Veterinary Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
| |
Collapse
|
15
|
Levodopa-Reduced Mucuna pruriens Seed Extract Shows Neuroprotective Effects against Parkinson's Disease in Murine Microglia and Human Neuroblastoma Cells, Caenorhabditis elegans, and Drosophila melanogaster. Nutrients 2018; 10:nu10091139. [PMID: 30131460 PMCID: PMC6164394 DOI: 10.3390/nu10091139] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 08/10/2018] [Accepted: 08/17/2018] [Indexed: 12/21/2022] Open
Abstract
Mucuna pruriens (Mucuna) has been prescribed in Ayurveda for various brain ailments including 'kampavata' (tremors) or Parkinson's disease (PD). While Mucuna is a well-known natural source of levodopa (L-dopa), published studies suggest that other bioactive compounds may also be responsible for its anti-PD effects. To investigate this hypothesis, an L-dopa reduced (<0.1%) M. pruriens seeds extract (MPE) was prepared and evaluated for its anti-PD effects in cellular (murine BV-2 microglia and human SH-SY5Y neuroblastoma cells), Caenorhabditis elegans, and Drosophila melanogaster models. In BV-2 cells, MPE (12.5⁻50 μg/mL) reduced hydrogen peroxide-induced cytotoxicity (15.7-18.6%), decreased reactive oxygen species production (29.1-61.6%), and lowered lipopolysaccharide (LPS)-induced nitric oxide species release by 8.9⁻60%. MPE (12.5-50 μg/mL) mitigated SH-SY5Y cell apoptosis by 6.9-40.0% in a non-contact co-culture assay with cell-free supernatants from LPS-treated BV-2 cells. MPE (12.5-50 μg/mL) reduced 6-hydroxydopamine (6-OHDA)-induced cell death of SH-SY5Y cells by 11.85⁻38.5%. Furthermore, MPE (12.5-50 μg/mL) increased median (25%) and maximum survival (47.8%) of C. elegans exposed to the dopaminergic neurotoxin, methyl-4-phenylpyridinium. MPE (40 μg/mL) ameliorated dopaminergic neurotoxin (6-OHDA and rotenone) induced precipitation of innate negative geotaxis behavior of D. melanogaster by 35.3 and 32.8%, respectively. Therefore, MPE contains bioactive compounds, beyond L-dopa, which may impart neuroprotective effects against PD.
Collapse
|
16
|
Sousa RDCS, Neves CMSS, Pereira MM, Freire MG, Coutinho JAP. Potential of Aqueous Two-Phase Systems for the Separation of Levodopa from Similar Biomolecules. JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY (OXFORD, OXFORDSHIRE : 1986) 2018; 93:1940-1947. [PMID: 30275632 PMCID: PMC6161814 DOI: 10.1002/jctb.5553] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 12/19/2017] [Indexed: 06/08/2023]
Abstract
BACKGROUND Levodopa is a precursor of several neurotransmitters, such as dopamine, and is used in the treatment of the Parkinson's disease. In this work, an alternative strategy was studied to separate levodopa from similar biomolecules using aqueous two-phase systems (ATPS). RESULTS Ternary ATPS composed of polyethylene glycol (PEG) 400 or ionic liquids (ILs), citrate buffer (K3C6H5O7/C6H8O7) at pH 7.0 and water, and quaternary ATPS composed of PEG 400, K3C6H5O7/C6H8O7 at pH 7.0, water and the same ILs at 5 wt%, were studied. The respective liquid-liquid phase diagrams were determined at 298 K to appraise the mixture compositions required to form two-phase systems, followed by studies of the partition of levodopa and structurally similar biomolecules (dopamine, L-phenylalanine, and L-tyrosine). Their partition coefficients and extraction efficiencies have been determined, and the selectivity of the ATPS to separate levodopa from the remaining biomolecules evaluated. CONCLUSION The results obtained indicated that PEG-based ATPS were the most effective to separate levodopa from L-phenylalanine while the separation from the other biomolecules was better using IL-based ATPS, in particular those based on [P4444]Cl and [N4444]Cl, with extraction efficiencies of levodopa to the salt-rich phase ranging between 62.7 and 74.0%, and of the remaining biomolecules to polymer/IL-rich phase up to 91.5%.
Collapse
Affiliation(s)
- Rita de Cássia S. Sousa
- CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
- Department of Chemistry, Federal University of Viçosa, 36570-000, Viçosa – MG, Brazil
| | - Catarina M. S. S. Neves
- CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
| | - Matheus M. Pereira
- CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
| | - Mara G. Freire
- CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
| | - João A. P. Coutinho
- CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
| |
Collapse
|
17
|
Singh SK, Dhawan SS. Analyzing trichomes and spatio-temporal expression of a cysteine protease gene Mucunain in Mucuna pruriens L. (DC). PROTOPLASMA 2018; 255:575-584. [PMID: 28975523 DOI: 10.1007/s00709-017-1164-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 08/31/2017] [Indexed: 06/07/2023]
Abstract
Mucuna pruriens is a well-known legume for the itching attributes of the trichome and a valuable medicinal herb that is used for the treatment of Parkinson's disease, sexual debilities, etc. Its cultivation was deprived due to its itching behavior. The wild genotype of M. pruriens have the largest trichome length (2015 ± 29 μm) compared to other genotype and mutants. The white-seeded variety of M. pruriens was found to be the most suitable for large-scale cultivation due to the small trichome size and less trichome density on the pod. The external surface trichomes have protuberance with unknown function. The unicellular trichomes of Mucuna show the flowing fluid or cytoplasm inside the trichome. The unigenes regulating the differentiation and development of the trichome such as GLABRA-1, GLABRA-2, and cpr-5 have been identified in M. pruriens transcriptome of the leaf. The Mucunain shows a higher transcript abundance in the flower and pod cover compared to the seeds. The Mucunain was found in every stage of plant growth, but it was highly expressed during maturity (about 170 days) with a high fragment per kilobase per million value.
Collapse
Affiliation(s)
- Susheel Kumar Singh
- CSIR-Central Institute of Medicinal And Aromatic Plants, P.O.-CIMAP, Lucknow, 226015, India
| | - Sunita Singh Dhawan
- CSIR-Central Institute of Medicinal And Aromatic Plants, P.O.-CIMAP, Lucknow, 226015, India.
| |
Collapse
|
18
|
Zanforlin E, Zagotto G, Ribaudo G. The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases. ACS Chem Neurosci 2017; 8:2356-2368. [PMID: 28862431 DOI: 10.1021/acschemneuro.7b00283] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Among the diseases affecting the central nervous system (CNS), neurodegenerations attract the interest of both the clinician and the medicinal chemist. The increasing average age of population, the growing number of patients, and the lack of long-term effective remedies push ahead the quest for novel tools against this class of pathologies. We present a review on the state of the art of the molecules (or combination of molecules) of natural origin that are currently under study against two well-defined pathologies: Parkinson's disease (PD) and Huntington's disease (HD). Nowadays, very few tools are available for preventing or counteracting the progression of such diseases. Two major parameters were considered for the preparation of this review: particular attention was reserved to these research works presenting well-defined molecular mechanisms for the studied compounds, and where available, papers reporting in vivo data were preferred. A literature search for peer-reviewed articles using PubMed, Scopus, and Reaxys databases was performed, exploiting different keywords and logical operators: 91 papers were considered (preferentially published after 2015). The review presents a brief overview on the etiology of the studied neurodegenerations and the current treatments, followed by a detailed discussion of the natural and semisynthetic compounds dividing them in different paragraphs considering their several mechanisms of action.
Collapse
Affiliation(s)
- Enrico Zanforlin
- Department of Pharmaceutical
and Pharmacological Sciences, University of Padova, Padova 35131, Italy
| | - Giuseppe Zagotto
- Department of Pharmaceutical
and Pharmacological Sciences, University of Padova, Padova 35131, Italy
| | - Giovanni Ribaudo
- Department of Pharmaceutical
and Pharmacological Sciences, University of Padova, Padova 35131, Italy
| |
Collapse
|
19
|
Cilia R, Laguna J, Cassani E, Cereda E, Pozzi NG, Isaias IU, Contin M, Barichella M, Pezzoli G. Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study. Neurology 2017; 89:432-438. [PMID: 28679598 PMCID: PMC5539737 DOI: 10.1212/wnl.0000000000004175] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Accepted: 05/05/2017] [Indexed: 11/15/2022] Open
Abstract
Objective: To investigate whether Mucuna pruriens (MP), a levodopa-containing leguminous plant growing in all tropical areas worldwide, may be used as alternative source of levodopa for indigent individuals with Parkinson disease (PD) who cannot afford long-term therapy with marketed levodopa preparations. Methods: We investigated efficacy and safety of single-dose intake of MP powder from roasted seeds obtained without any pharmacologic processing. Eighteen patients with advanced PD received the following treatments, whose sequence was randomized: (1) dispersible levodopa at 3.5 mg/kg combined with the dopa-decarboxylase inhibitor benserazide (LD+DDCI; the reference treatment); (2) high-dose MP (MP-Hd; 17.5 mg/kg); (3) low-dose MP (MP-Ld; 12.5 mg/kg); (4) pharmaceutical preparation of LD without DDCI (LD−DDCI; 17.5 mg/kg); (5) MP plus benserazide (MP+DDCI; 3.5 mg/kg); (6) placebo. Efficacy outcomes were the change in motor response at 90 and 180 minutes and the duration of on state. Safety measures included any adverse event (AE), changes in blood pressure and heart rate, and the severity of dyskinesias. Results: When compared to LD+DDCI, MP-Ld showed similar motor response with fewer dyskinesias and AEs, while MP-Hd induced greater motor improvement at 90 and 180 minutes, longer ON duration, and fewer dyskinesias. MP-Hd induced less AEs than LD+DDCI and LD−DDCI. No differences in cardiovascular response were recorded. Conclusion: Single-dose MP intake met all noninferiority efficacy and safety outcome measures in comparison to dispersible levodopa/benserazide. Clinical effects of high-dose MP were similar to levodopa alone at the same dose, with a more favorable tolerability profile. ClinicalTrials.gov identifier: NCT02680977.
Collapse
Affiliation(s)
- Roberto Cilia
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy.
| | - Janeth Laguna
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy
| | - Erica Cassani
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy
| | - Emanuele Cereda
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy
| | - Nicolò G Pozzi
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy
| | - Ioannis U Isaias
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy
| | - Manuela Contin
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy
| | - Michela Barichella
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy
| | - Gianni Pezzoli
- From the Parkinson Institute (R.C., E. Cassani, M.B., G.P.), ASST Gaetano Pini-CTO, Milan, Italy; Neurology Clinic (J.L.), Clinica Niño Jesus, Santa Cruz, Bolivia; Nutrition and Dietetics Service (E. Cereda), Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Pathophysiology and Transplantation (N.G.P., I.U.I.), LAMB Pierfranco & Luisa Mariani, University of Milan, Italy; Department of Neurology (N.G.P., I.U.I.), University Hospital Würzburg and Julius-Maximilians-University, Würzburg, Germany; IRCCS-Institute of Neurological Sciences of Bologna (M.C.); and Department of Biomedical and Neuromotor Sciences (M.C.), University of Bologna, Italy
| |
Collapse
|
20
|
Differential effects of phytotherapic preparations in the hSOD1 Drosophila melanogaster model of ALS. Sci Rep 2017; 7:41059. [PMID: 28102336 PMCID: PMC5244478 DOI: 10.1038/srep41059] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Accepted: 12/15/2016] [Indexed: 11/15/2022] Open
Abstract
The present study was aimed at characterizing the effects of Withania somnifera (Wse) and Mucuna pruriens (Mpe) on a Drosophila melanogaster model for Amyotrophic Lateral Sclerosis (ALS). In particular, the effects of Wse and Mpe were assessed following feeding the flies selectively overexpressing the wild human copper, zinc-superoxide dismutase (hSOD1-gain-of-function) in Drosophila motoneurons. Although ALS-hSOD1 mutants showed no impairment in life span, with respect to GAL4 controls, the results revealed impairment of climbing behaviour, muscle electrophysiological parameters (latency and amplitude of ePSPs) as well as thoracic ganglia mitochondrial functions. Interestingly, Wse treatment significantly increased lifespan of hSDO1 while Mpe had not effect. Conversely, both Wse and Mpe significantly rescued climbing impairment, and also latency and amplitude of ePSPs as well as failure responses to high frequency DLM stimulation. Finally, mitochondrial alterations were any more present in Wse- but not in Mpe-treated hSOD1 mutants. Hence, given the role of inflammation in the development of ALS, the high translational impact of the model, the known anti-inflammatory properties of these extracts, and the viability of their clinical use, these results suggest that the application of Wse and Mpe might represent a valuable pharmacological strategy to counteract the progression of ALS and related symptoms.
Collapse
|
21
|
Singh SK, Yadav D, Lal RK, Gupta MM, Dhawan SS. Inducing mutations through γ-irradiation in seeds of Mucuna pruriens for developing high L-DOPA-yielding genotypes. Int J Radiat Biol 2016; 93:426-432. [PMID: 27897091 DOI: 10.1080/09553002.2016.1254832] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
PURPOSE To develop elite genotypes in Mucuna pruriens (L.) DC with high L-DOPA (L-3, 4 dihydroxyphenylalanine) yields, with non-itching characteristics and better adaptability by applying γ-irradiation. Molecular and chemical analysis was performed for screening based on specific characteristics desired for developing suitable genotypes. MATERIALS AND METHODS Developed, mutant populations were analyzed for L-DOPA % in seeds through TLC (thin layer chromatography), and the results obtained were validated with the HPLC (High performance liquid chromatography). The DNA (Deoxyribonucleic acid) was isolated from the leaf at the initial stage and used for DNA polymorphism. RNA (Ribonucleic acid) was isolated from the leaf during maturity and used for expression analysis. RESULTS The selected mutant T-I-7 showed 5.7% L-DOPA content compared to 3.18% of parent CIM-Ajar. The total polymorphism obtained was 57% with the molecular marker analysis. The gene expression analysis showed higher fold change expression of the dopadecarboxylase gene (DDC) in control compared to selected mutants (T-I-7, T-II-23, T-IV-9, T-VI-1). CONCLUSION DNA polymorphism was used for the screening of mutants for efficient screening at an early stage. TLC was found suitable for the large-scale comparative chemical analysis of L-DOPA. The expression profile of DDC clearly demonstrated the higher yields of L-DOPA in selected mutants developed by γ-irradiation in the seeds of the control.
Collapse
Affiliation(s)
- Susheel Kumar Singh
- a Council of Scientific and Industrial Research (CSIR), Central Institute of Medicinal and Aromatic Plants (CIMAP) , Lucknow , India
| | - Deepti Yadav
- a Council of Scientific and Industrial Research (CSIR), Central Institute of Medicinal and Aromatic Plants (CIMAP) , Lucknow , India
| | - Raj Kishori Lal
- a Council of Scientific and Industrial Research (CSIR), Central Institute of Medicinal and Aromatic Plants (CIMAP) , Lucknow , India
| | - Madan M Gupta
- a Council of Scientific and Industrial Research (CSIR), Central Institute of Medicinal and Aromatic Plants (CIMAP) , Lucknow , India
| | - Sunita Singh Dhawan
- a Council of Scientific and Industrial Research (CSIR), Central Institute of Medicinal and Aromatic Plants (CIMAP) , Lucknow , India
| |
Collapse
|
22
|
Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. Clin Neuropharmacol 2016; 38:201-3. [PMID: 26366963 DOI: 10.1097/wnf.0000000000000098] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES We compared levodopa (LD) kinetic-dynamic profile of a dose of LD/aromatic amino acid decarboxylase peripheral inhibitors versus a nominally equivalent dose of a commercial Mucuna pruriens (Mucuna) seeds extract in 2 patients with Parkinson disease chronically taking LD standard combined with self-prescribed Mucuna. METHODS Patients were challenged with a fasting morning dose of 100 mg LD/25 mg carbidopa (patient 1) or benserazide (patient 2) versus 100 mg LD from Mucuna capsules in 2 different sessions, after a 12-hour standard LD formulations' washout. They underwent kinetic-dynamic LD monitoring based on LD dose intake and simultaneous serial assessments of plasma drug concentrations and motor test performances. Quantitative analysis of LD in Mucuna capsules was also performed. RESULTS Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna. In patient 1, impaired LD bioavailability from Mucuna resulted in reduced duration and overall extent of drug response compared with LD/carbidopa. In patient 2, no significant subacute LD motor response was observed in either condition. Quantitative analysis of Mucuna formulation confirmed the 100 mg LD content for the utilized capsules. CONCLUSIONS Our results show an impaired LD bioavailability from Mucuna preparation, as expected by the lacking aromatic amino acid decarboxylase inhibitors coadministration, which might explain the suggested lower dyskinetic potential of Mucuna compared with standard LD formulations.
Collapse
|
23
|
Cassani E, Cilia R, Laguna J, Barichella M, Contin M, Cereda E, Isaias IU, Sparvoli F, Akpalu A, Budu KO, Scarpa MT, Pezzoli G. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. J Neurol Sci 2016; 365:175-80. [PMID: 27206902 DOI: 10.1016/j.jns.2016.04.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 03/17/2016] [Accepted: 04/03/2016] [Indexed: 10/21/2022]
Abstract
BACKGROUND Parkinson's disease (PD) is a progressive neurological condition. Levodopa (LD) is the gold standard therapy for PD patients. Most PD patients in low-income areas cannot afford long-term daily Levodopa therapy. The aim of our study was to investigate if Mucuna pruriens (MP), a legume with high LD content that grows in tropical regions worldwide, might be potential alternative for poor PD patients. METHODS We analyzed 25 samples of MP from Africa, Latin America and Asia. We measured the content in LD in various MP preparations (dried, roasted, boiled). LD pharmacokinetics and motor response were recorded in four PD patients, comparing MP vs. LD+Dopa-Decarboxylase Inhibitor (DDCI) formulations. RESULTS Median LD concentration in dried MP seeds was 5.29%; similar results were obtained in roasted powder samples (5.3%), while boiling reduced LD content up to 70%. Compared to LD+DDCI, MP extract at similar LD dose provided less clinical benefit, with a 3.5-fold lower median AUC. CONCLUSION Considering the lack of a DDCI, MP therapy may provide clinical benefit only when content of LD is at least 3.5-fold the standard LD+DDCI. If long-term MP proves to be safe and effective in controlled clinical trials, it may be a sustainable alternative therapy for PD in low-income countries.
Collapse
Affiliation(s)
- Erica Cassani
- Parkinson Institute, ASST G.Pini-CTO, ex ICP, Milan, Italy.
| | - Roberto Cilia
- Parkinson Institute, ASST G.Pini-CTO, ex ICP, Milan, Italy
| | - Janeth Laguna
- Neurology Clinic, Clinica Niño Jesus, Santa Cruz, Bolivia
| | | | - Manuela Contin
- IRCCS-Institute of Neurological Sciences of Bologna, Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Emanuele Cereda
- Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Ioannis U Isaias
- Department of Pathophysiology and Transplantation, LAMB Pierfranco & Luisa Mariani, University of Milan, Milan, Italy
| | | | | | - Kwabena Ofosu Budu
- Institute of Agricultural Research, College of Agriculture & Consumer Sciences, University of Ghana, Ghana
| | | | - Gianni Pezzoli
- Parkinson Institute, ASST G.Pini-CTO, ex ICP, Milan, Italy
| |
Collapse
|
24
|
Mannangatti P, Naidu KN. Indian Herbs for the Treatment of Neurodegenerative Disease. ADVANCES IN NEUROBIOLOGY 2016; 12:323-36. [PMID: 27651261 DOI: 10.1007/978-3-319-28383-8_17] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Ayurveda, an ancient system of medicine that is indigenous to India, is believed to be the world's oldest comprehensive health-care system and is now one of the most recognized and widely practiced disciplines of alternative medicine in the world. Medicinal herbs have been in use for treating diseases since ancient times in India. Ayurvedic therapies with medicinal herbs and herbomineral products generally provide relief without much adverse effects even after prolonged administration. Neurodegenerative disorders are a major cause of mortality and disability, and increasing life spans represent one of the key challenges of medical research. Ayurvedic medicine describes most neurodegenerative diseases and has defined a number of plants with therapeutic benefits for the treatment of neurodegenerative diseases having antioxidant activities. In this chapter, the role of four important Ayurvedic medicinal plants, viz., Withania somnifera (ashwagandha), Bacopa monnieri (brahmi), Centella asiatica (gotu kola), and Mucuna pruriens (velvet bean), on neurodegenerative diseases are discussed.
Collapse
Affiliation(s)
- Padmanabhan Mannangatti
- Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
| | | |
Collapse
|
25
|
Venkiteswaran K, Alexander DN, Puhl MD, Rao A, Piquet AL, Nyland JE, Subramanian MP, Iyer P, Boisvert MM, Handly E, Subramanian T, Grigson PS. Transplantation of human retinal pigment epithelial cells in the nucleus accumbens of cocaine self-administering rats provides protection from seeking. Brain Res Bull 2015; 123:53-60. [PMID: 26562520 DOI: 10.1016/j.brainresbull.2015.11.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Revised: 10/30/2015] [Accepted: 11/05/2015] [Indexed: 01/05/2023]
Abstract
Chronic exposure to drugs and alcohol leads to damage to dopaminergic neurons and their projections in the 'reward pathway' that originate in the ventral tegmental area (VTA) and terminate in the nucleus accumbens (NAc). This damage is thought to contribute to the signature symptom of addiction: chronic relapse. In this study we show that bilateral transplants of human retinal pigment epithelial cells (RPECs), a cell mediated dopaminergic and trophic neuromodulator, into the medial shell of the NAc, rescue rats with a history of high rates of cocaine self-administration from drug-seeking when returned, after 2 weeks of abstinence, to the drug-associated chamber under extinction conditions (i.e., with no drug available). Excellent survival was noted for the transplant of RPECs in the shell and/or the core of the NAc bilaterally in all rats that showed behavioral recovery from cocaine seeking. Design based unbiased stereology of tyrosine hydroxylase (TH) positive cell bodies in the VTA showed better preservation (p<0.035) in transplanted animals compared to control animals. This experiment shows that the RPEC graft provides beneficial effects to prevent drug seeking in drug addiction via its effects directly on the NAc and its neural network with the VTA.
Collapse
Affiliation(s)
- Kala Venkiteswaran
- Department of Neurology, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA; Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Danielle N Alexander
- Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Matthew D Puhl
- Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Anand Rao
- Department of Neurology, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Amanda L Piquet
- Department of Neurology, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Jennifer E Nyland
- Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Megha P Subramanian
- Department of Neurology, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA; Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Puja Iyer
- Department of Neurology, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Matthew M Boisvert
- Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Erin Handly
- Department of Neurology, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA; Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Thyagarajan Subramanian
- Department of Neurology, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA; Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| | - Patricia Sue Grigson
- Department of Neural and Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
| |
Collapse
|
26
|
Mechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments. Curr Neurol Neurosci Rep 2014; 14:451. [PMID: 24760476 DOI: 10.1007/s11910-014-0451-y] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
At least 40% of patients with Parkinson's disease (PD) use one or more forms of alternative therapy (AT) to complement standard treatments. This article reviews the commonest forms of AT for PD, including acupuncture, tai chi, yoga, mindfulness, massage, herbal medicine, and cannabis. We discuss the current evidence for the clinical efficacy of each AT and discuss potential mechanisms, including those suggested by animal and human studies. With a few notable exceptions, none of the treatments examined were investigated rigorously enough to draw definitive conclusions about efficacy or mechanism. Tai chi, acupuncture, Mucuna pruriens, cannabinoids, and music therapy have all been proposed to work through specific mechanisms, although current evidence is insufficient to support or refute these claims, with the possible exception of Mucuna pruriens (which contains levodopa). It is likely that most ATs predominantly treat PD patients through general mechanisms, including placebo effects, stress reduction, and improved mood and sleep, and AT may provide patients with a greater locus of control regarding their illness.
Collapse
|
27
|
Poddighe S, De Rose F, Marotta R, Ruffilli R, Fanti M, Secci PP, Mostallino MC, Setzu MD, Zuncheddu MA, Collu I, Solla P, Marrosu F, Kasture S, Acquas E, Liscia A. Mucuna pruriens (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson's disease. PLoS One 2014; 9:e110802. [PMID: 25340511 PMCID: PMC4207759 DOI: 10.1371/journal.pone.0110802] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Accepted: 09/17/2014] [Indexed: 01/02/2023] Open
Abstract
The fruit fly Drosophila melanogaster (Dm) mutant for PTEN-induced putative kinase 1 (PINK1B9) gene is a powerful tool to investigate physiopathology of Parkinson's disease (PD). Using PINK1B9 mutant Dm we sought to explore the effects of Mucuna pruriens methanolic extract (Mpe), a L-Dopa-containing herbal remedy of PD. The effects of Mpe on PINK1B9 mutants, supplied with standard diet to larvae and adults, were assayed on 3-6 (I), 10-15 (II) and 20-25 (III) days old flies. Mpe 0.1% significantly extended lifespan of PINK1B9 and fully rescued olfactory response to 1-hexanol and improved climbing behavior of PINK1B9 of all ages; in contrast, L-Dopa (0.01%, percentage at which it is present in Mpe 0.1%) ameliorated climbing of only PINK1B9 flies of age step II. Transmission electron microscopy analysis of antennal lobes and thoracic ganglia of PINK1B9 revealed that Mpe restored to wild type (WT) levels both T-bars and damaged mitochondria. Western blot analysis of whole brain showed that Mpe, but not L-Dopa on its own, restored bruchpilot (BRP) and tyrosine hydroxylase (TH) expression to age-matched WT control levels. These results highlight multiple sites of action of Mpe, suggesting that its effects cannot only depend upon its L-Dopa content and support the clinical observation of Mpe as an effective medication with intrinsic ability of delaying the onset of chronic L-Dopa-induced long-term motor complications. Overall, this study strengthens the relevance of using PINK1B9 Dm as a translational model to study the properties of Mucuna pruriens for PD treatment.
Collapse
Affiliation(s)
- Simone Poddighe
- Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
| | | | - Roberto Marotta
- Electron Microscopy Lab, Nanochemistry Department, Istituto Italiano di Tecnologia, Genoa, Italy
| | - Roberta Ruffilli
- Electron Microscopy Lab, Nanochemistry Department, Istituto Italiano di Tecnologia, Genoa, Italy
| | - Maura Fanti
- Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
| | | | | | | | | | - Ignazio Collu
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
| | - Paolo Solla
- Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy
| | - Francesco Marrosu
- Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy
| | - Sanjay Kasture
- Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Ahmednagar, Maharashtra, India
| | - Elio Acquas
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
- Center of Excellence for the Study of Neurobiology of Addiction, University of Cagliari, Cagliari, Italy
- National Institute of Neuroscience - INN, University of Cagliari, Cagliari, Italy
| | - Anna Liscia
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
| |
Collapse
|